- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
- Interventions
- Ivosidenib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 10,564
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-3512676 + Erlotinib, Erlotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 35
- States / cities
- Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
- Conditions
- Epilepsy, Epilepsies, Partial
- Interventions
- oxcarbazepine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 3 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 21 more
- Conditions
- Achondroplasia
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years to 15 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Torrance, California • Wilmington, Delaware + 7 more
- Conditions
- Gout, Chronic Kidney Disease (CKD)
- Interventions
- Lesinurad, XOI, Placebo, colchicine, corticosteroids
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
- Conditions
- Sickle Cell, Diabetes, Cancer, Cardiovascular Disease, Genetic Screening
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,061 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Cincinnati, Ohio • Lewisburg, Pennsylvania
- Conditions
- Parkinson Disease, Sleep Disorder, Fatigue
- Interventions
- SunRay Light Boxes
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 20 more
- Conditions
- Cocaine-Related Disorders
- Interventions
- Lamotrigine
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 59 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 12
- States / cities
- Sedona, Arizona • Denver, Colorado • Arlington Heights, Illinois + 8 more
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Vericiguat, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 84
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 74 more
- Conditions
- Growth Hormone Disorder, Growth Hormone Deficiency in Children, Growth Disorder, Idiopathic Short Stature
- Interventions
- somatropin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 40
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 34 more
- Conditions
- Opioid Abuse, Prescription Drug Abuse (Not Dependent)
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,464 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Salt Lake City, Utah
- Conditions
- Family Caregivers, Stroke
- Interventions
- Telehealth Assessment and Skill-Building Kit (TASK III) Group, Information Support and Referral (ISR) Group
- Behavioral
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Osteoarthritis, Knee
- Interventions
- Ibuprofen, celecoxib, placebo
- Drug · Other
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 33
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 30 more
- Conditions
- Birth Outcomes, Safety, Adverse Event Following Immunization
- Interventions
- mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 2 more
- Conditions
- Breast Cancer
- Interventions
- 3D-Conformal External Beam
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 57
- States / cities
- Peoria, Arizona • Burbank, California • Aurora, Colorado + 44 more
- Conditions
- COVID-19
- Interventions
- Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 127
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more
- Conditions
- Coagulopathy, Hemorrhage
- Interventions
- Autologous Spray Dried Plasma
- Combination Product
- Lead sponsor
- Velico Medical
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Milwaukee, Wisconsin • West Bend, Wisconsin
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Notal Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Lakewood, Colorado • Orlando, Florida • Cincinnati, Ohio + 2 more
- Conditions
- Pain
- Interventions
- Oxycodone
- Drug
- Lead sponsor
- VistaPharm, Inc.
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 9
- States / cities
- Orange, California • Miami, Florida • Tampa, Florida + 5 more
- Conditions
- Crohn's Disease
- Interventions
- Filgotinib, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 100
- States / cities
- Dothan, Alabama • Sun City, Arizona • Coronado, California + 80 more
- Conditions
- Lymphoma, Follicular
- Interventions
- Bevacizumab, Rituximab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 22
- States / cities
- Jonesboro, Arkansas • Fort Myers, Florida • Jacksonville, Florida + 17 more
- Conditions
- Chronic Rhinitis
- Interventions
- RhinAer Stylus, Sham
- Device
- Lead sponsor
- Aerin Medical
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- Roseville, California • Torrance, California • Plantation, Florida + 10 more